Literature DB >> 7741981

Avoidance and management of adverse reactions to antituberculosis drugs.

A M Patel1, J McKeon.   

Abstract

Potent antibiotics are required to cure tuberculosis and reduce the burden of illness in the community. Minor adverse effects are commonly encountered and can be managed by reassurance and explanation. Significant hypersensitivity reactions require cessation of all antituberculosis drugs. Adverse effects should be treated appropriately. An effective antituberculosis regimen should be reestablished as soon as possible. Desensitisation may be necessary if suitable alternative drugs cannot be used. In the event of drug-induced hepatitis, all hepatotoxic drugs should be ceased until symptoms resolve and liver function tests return to normal. Other significant direct toxic effects should be promptly detected and appropriately treated. A thorough knowledge of potential adverse reactions and pharmacokinetics is essential for any physician using antituberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7741981     DOI: 10.2165/00002018-199512010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  143 in total

Review 1.  Tuberculosis and pregnancy.

Authors:  M A Hamadeh; J Glassroth
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

2.  Disseminated intravascular coagulopathy associated with rifampicin.

Authors:  M Ip; K P Cheng; W C Cheung
Journal:  Tubercle       Date:  1991-12

3.  Interaction of ketoconazole with rifampin and isoniazid.

Authors:  P C Craven
Journal:  N Engl J Med       Date:  1985-04-18       Impact factor: 91.245

4.  Effect of rifampin on chloramphenicol levels.

Authors:  C G Prober
Journal:  N Engl J Med       Date:  1985-03-21       Impact factor: 91.245

5.  A service programme with a 6-month intensive chemotherapy regimen in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong.

Authors: 
Journal:  Tubercle       Date:  1983-12

6.  Drug-induced liver injury.

Authors:  J R Mitchell; B H Lauterburg
Journal:  Hosp Pract       Date:  1978-09

7.  Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis.

Authors:  W R Wilson; C J Wilkowske; A J Wright; M A Sande; J E Geraci
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

8.  Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide.

Authors:  G A Ellard; R M Haslam
Journal:  Tubercle       Date:  1976-06

9.  Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

Authors:  A Kumar; P K Misra; R Mehotra; Y C Govil; G S Rana
Journal:  Am Rev Respir Dis       Date:  1991-06

10.  Insidious rifampin-associated renal failure with light-chain proteinuria.

Authors:  R J Warrington; G R Hogg; F Paraskevas; K S Tse
Journal:  Arch Intern Med       Date:  1977-07
View more
  4 in total

1.  Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.

Authors:  A C Miller; I Y Gelmanova; S Keshavjee; S Atwood; G Yanova; S Mishustin; J J Furin; S S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2012-04-09       Impact factor: 2.373

Review 2.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

3.  A case report. Rediscovering tuberculostatics drugs: skin rash and pyrazinamide.

Authors:  S Calpena Martínez; I Carrillo Acosta; B Álvarez Álvarez; M Górgolas Hernández-Mora
Journal:  Rev Esp Quimioter       Date:  2022-03-01       Impact factor: 2.515

4.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.